rs786202081
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_144997.7(FLCN):c.250-1G>A variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_144997.7 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Publications
- Birt-Hogg-Dube syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Orphanet, ClinGen
- Birt-Hogg-Dube syndrome 1Inheritance: AD Classification: DEFINITIVE Submitted by: G2P, Ambry Genetics
- familial spontaneous pneumothoraxInheritance: AD Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet, Ambry Genetics
- renal carcinomaInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- colorectal cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| FLCN | NM_144997.7 | c.250-1G>A | splice_acceptor_variant, intron_variant | Intron 4 of 13 | ENST00000285071.9 | NP_659434.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| FLCN | ENST00000285071.9 | c.250-1G>A | splice_acceptor_variant, intron_variant | Intron 4 of 13 | 1 | NM_144997.7 | ENSP00000285071.4 | |||
| ENSG00000264187 | ENST00000427497.3 | n.148+1667G>A | intron_variant | Intron 4 of 11 | 1 | ENSP00000394249.3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Birt-Hogg-Dube syndrome Pathogenic:4
This sequence change affects an acceptor splice site in intron 4 of the FLCN gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in FLCN are known to be pathogenic (PMID: 15852235). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with Birt-Hogg-Dubé syndrome (PMID: 15852235, 18234728). This variant is also known as IVS4-1G>A. ClinVar contains an entry for this variant (Variation ID: 185318). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
- -
This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. -
- -
not provided Pathogenic:1
Canonical splice site variant predicted to result in an in-frame loss of the adjacent exon in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 19802896, 21937013, 28152038, 29357828, 15852235) -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.250-1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide before coding exon 2 of the FLCN gene. This alteration has been identified in multiple family members diagnosed with Birt-Hogg-Dube (Schmidt LS et al. Am. J. Hum. Genet. 2005 Jun; 76(6):1023-33). Of note, this alteration is also known as IVS4-1G>A in published literature. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site. In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at